![Digital Systems Expected to Drive 5% Annual Growth in PCR Testing Products](https://www.g2intelligence.com/wp-content/uploads/2023/01/Jan23.LIR_.PCRTestMarket-iStock-1800x1250-1-1080x675.jpg)
Digital Systems Expected to Drive 5% Annual Growth in PCR Testing Products
The total market for PCR products will likely top $5 billion in 2023, according to a new report.
The total market for PCR products will likely top $5 billion in 2023, according to a new report.
M&A activity in the clinical diagnostics space was significantly down in 2022 in terms of both deal volume and deal value.
Congress fails to include SALSA in the omnibus federal government spending bill passed at the end of 2022, but delays PAMA price cuts once again.
In our latest roundup, schemes involving cancer genetic testing and kickbacks remain the most common, but there were some surprises.
Key cases over the last month include a CGx testing kickback scheme, false billing, and violations of a non-compete clause and HIPAA.
Laboratories may have to revise their own medical records disclosure policies to ensure compliance.
Here are the changes to Medicare specimen collection fee and travel allowances included in the 2023 PFS and what you’ll need to know to comply.
One of the biggest danger areas that labs and their billing staffs face in COVID-19 test reimbursement is improper use of HCPCS code G2023.
How to steer clear of assumptions commonly made by employers that can lead to citations under SEC. 1904.32 of the OSHA recordkeeping standard.
In this month’s diagnostics pipeline report, Roche gets clearance for two new Alzheimer’s early detection tests.